ClinicalTrials.gg
CompletedNCT05494736Updated Mar 26, 2025Results posted

MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)

A Phase 1 interventional study of MK-8527 in Human Immunodeficiency Virus, sponsored by Merck Sharp & Dohme LLC. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-03-26.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a single-dose clinical study to evaluate the safety, tolerability, pharmacokinetics, and anti-retroviral activity of MK-8527 in antiretroviral therapy (ART)-naïve participants living with human immunodeficiency virus type 1 (HIV-1) infection. The primary hypothesis is that, at a dose that is safe and generally well tolerated, MK-8527 will have antiretroviral activity as measured by a reduction from baseline in plasma HIV-1 ribonucleic acid (RNA) of ≥1.0 log10 copies/mL. A total of 4 arms was initially planned but Arm D was never initiated as the primary objectives were achieved following completion of Arms A to C.

02

Conditions studied

  • Human Immunodeficiency Virus

Browse trials for

03

In context

Acquired Immunodeficiency Syndrome Unverified

3,037 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's enrollment of 20 is below the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is in good health other than -1 infection
  • Is documented HIV-1 positive
  • Is ART-naïve, which is defined as not having received any marketed antiretroviral agent for treatment of HIV-1 infection (prior use of an ART for PrEP or therapy is permitted if the last dose was ≥30 days prior to study drug administration)
  • Is willing to receive no other ART for the monitoring period of this study

Exclusion criteria

Exclusion Criteria:

  • Has a history of endocrine, GI, cardiovascular, hematological, hepatic, immunological (outside of -1 infection), renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Is unable to refrain from or anticipates the use of any medication, including prescription and nonprescription drugs or herbal remedies beginning approximately 2 weeks (or 5 half-lives) prior to administration of the initial dose of study intervention, throughout the study, until the poststudy visit
  • Has participated in another study within 4 weeks (or 5 half-lives, whichever is greater) prior to the prestudy (screening) visit
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Panel A: MK-8527 1.0 mg

    Participants receive a single oral dose of MK-8527 1.0 mg.

    Drug: MK-8527

  • Experimental
    Panel B: MK-8527 0.5 mg

    Participants receive a single oral dose of MK-8527 0.5 mg.

    Drug: MK-8527

  • Experimental
    Panel C: MK-8527 0.25 mg

    Participants receive a single oral dose of MK-8527 0.25 mg.

    Drug: MK-8527

Interventions

  • MK-8527 capsule taken by mouth.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA)

    The mean change from baseline in HIV-1 RNA counts at 168 hours after a single doses of MK-8527 is reported.

    Time frame: Baseline and 168 hours postdose on Day 1

  2. Number of Participants Experiencing ≥1 Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 28 days

  3. Number of Participants Discontinuing From Study Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 28 days

Secondary outcomes

  1. Area Under the Concentration-Time Curve From Predose to 168 Hours Postdose (AUC0-168) of MK-8527 Triphosphate (MK-8527-TP) in Peripheral Blood Mononuclear Cells (PBMCs)

    The AUC0-168 of MK-8527-TP in PBMCs is reported.

    Time frame: Predose and 4, 12, 24, 96, 120, 144, and 168 hours postdose

  2. Area Under the Concentration-Time Curve From Predose to Infinity (AUC0-inf) of MK-8527-TP in PBMCs

    The MK-8527-TP AUC0-inf in PBMCs is reported.

    Time frame: Predose and 4, 12, 24, 96, 120, 144, 168, 192, 240, 336, 504, and 672 hours postdose

  3. Area Under the Concentration-Time Curve From Predose to Last Measurable Concentration (AUC0-last) of MK-8527-TP in PBMCs

    The MK-8527-TP AUC0-last in PBMCs is reported.

    Time frame: Predose and 4, 12, 24, 96, 120, 144, 168, 192, 240, 336, 504, and 672 hours postdose

  4. Maximum Concentration (Cmax) of MK-8527-TP in PBMCs

    The MK-8527-TP Cmax in PBMCs is reported.

    Time frame: Predose and 4, 12, 24, 96, 120, 144, 168, 192, 240, 336, 504, and 672 hours postdose

  5. Concentration at 168 Hours Postdose (C168) of MK-8527-TP in PBMCs

    The C168 of MK-8527-TP in PBMCs is reported.

    Time frame: 168 hours postdose

  6. Time to Maximum Concentration (Tmax) of MK-8527-TP in PBMCs

    The MK-8527-TP Tmax in PBMCs is reported.

    Time frame: Predose and 4, 12, 24, 96, 120, 144, 168, 192, 240, 336, 504, and 672 hours postdose

  7. Apparent Terminal Half-life (t½) of MK-8527-TP in PBMCs

    The apparent t½ of MK-8527-TP in PBMCs is reported.

    Time frame: Predose and 4, 12, 24, 96, 120, 144, 168, 192, 240, 336, 504, and 672 hours postdose

  8. AUC0-inf of MK-8527 in Plasma

    The AUC0-inf of MK-8527 in plasma is reported.

    Time frame: Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose

  9. AUC0-last of MK-8527 in Plasma

    The AUC0-last of MK-8527 in plasma is reported.

    Time frame: Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose

  10. Clast of MK-8527 in Plasma

    The Clast of MK-8527 in plasma is reported.

    Time frame: Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose

  11. Cmax of MK-8527 in Plasma

    The Cmax of MK-8527 in plasma is reported.

    Time frame: Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose

  12. Tmax of MK-8527 in Plasma

    The Tmax of MK-8527 in plasma is reported.

    Time frame: Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose

  13. Apparent t½ of MK-8527 in Plasma

    The apparent t½ of MK-8527 in plasma is reported.

    Time frame: Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose

  14. Correlation Between Intracellular C168 of MK-8527-TP in PBMCs and Change From Baseline in Plasma HIV-1 RNA

    The correlation between between the C168 of MK-8527-TP in PBMCs and the change from baseline in plasma HIV-1 RNA levels 168 hours after dosing was calculated based on all pooled participants. All participants who complied with the protocol sufficiently to ensure that generated data will belikely to exhibit the effects of treatment, according to the underlying scientific model, are included. Participants with data below the LLOQ are excluded.

    Time frame: Predose and 168 hours postdose

07

Results

Posted Mar 26, 2025

Participant flow

Participant flow — Overall Study
MilestonePanel A: MK-8527 1.0 mgPanel B: MK-8527 0.5 mgPanel C: MK-8527 0.25 mg
Started866
Completed866
Not completed000

Outcome measures

PrimaryChange From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA)

The mean change from baseline in HIV-1 RNA counts at 168 hours after a single doses of MK-8527 is reported.

Time frame:
Baseline and 168 hours postdose on Day 1
Reported as:
Least squares mean · HIV-1 RNA copies/mL
Change From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA)
HIV-1 RNA copies/mLPanel A: MK-8527 1.0 mgPanel B: MK-8527 0.5 mgPanel C: MK-8527 0.25 mg
Change From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA)-1.38 (-1.61 to -1.15)-1.40 (-1.66 to -1.13)-0.80 (-1.06 to -0.53)
PrimaryNumber of Participants Experiencing ≥1 Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Number of Participants Experiencing ≥1 Adverse Event (AE)
ParticipantsPanel A: MK-8527 1.0 mgPanel B: MK-8527 0.5 mgPanel C: MK-8527 0.25 mg
Number of Participants Experiencing ≥1 Adverse Event (AE)552
PrimaryNumber of Participants Discontinuing From Study Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Number of Participants Discontinuing From Study Due to an AE
ParticipantsPanel A: MK-8527 1.0 mgPanel B: MK-8527 0.5 mgPanel C: MK-8527 0.25 mg
Number of Participants Discontinuing From Study Due to an AE000
SecondaryArea Under the Concentration-Time Curve From Predose to 168 Hours Postdose (AUC0-168) of MK-8527 Triphosphate (MK-8527-TP) in Peripheral Blood Mononuclear Cells (PBMCs)

The AUC0-168 of MK-8527-TP in PBMCs is reported.

Time frame:
Predose and 4, 12, 24, 96, 120, 144, and 168 hours postdose
Reported as:
Least squares mean · h*pmol/10^6 cells
Area Under the Concentration-Time Curve From Predose to 168 Hours Postdose (AUC0-168) of MK-8527 Triphosphate (MK-8527-TP) in Peripheral Blood Mononuclear Cells (PBMCs)
h*pmol/10^6 cellsPanel A: MK-8527 1.0 mgPanel B: MK-8527 0.5 mgPanel C: MK-8527 0.25 mg
Area Under the Concentration-Time Curve From Predose to 168 Hours Postdose (AUC0-168) of MK-8527 Triphosphate (MK-8527-TP) in Peripheral Blood Mononuclear Cells (PBMCs)29.2 (24.1 to 35.3)12.6 (10.1 to 15.7)5.53 (4.44 to 6.89)
SecondaryArea Under the Concentration-Time Curve From Predose to Infinity (AUC0-inf) of MK-8527-TP in PBMCs

The MK-8527-TP AUC0-inf in PBMCs is reported.

Time frame:
Predose and 4, 12, 24, 96, 120, 144, 168, 192, 240, 336, 504, and 672 hours postdose
Reported as:
Geometric mean · h*pmol/10^6 cells
Area Under the Concentration-Time Curve From Predose to Infinity (AUC0-inf) of MK-8527-TP in PBMCs
h*pmol/10^6 cellsPanel A: MK-8527 1.0 mgPanel B: MK-8527 0.5 mgPanel C: MK-8527 0.25 mg
Area Under the Concentration-Time Curve From Predose to Infinity (AUC0-inf) of MK-8527-TP in PBMCs47.7 (37.8 to 60.3)24.5 (18.7 to 32.1)8.87 (6.60 to 11.9)
SecondaryArea Under the Concentration-Time Curve From Predose to Last Measurable Concentration (AUC0-last) of MK-8527-TP in PBMCs

The MK-8527-TP AUC0-last in PBMCs is reported.

Time frame:
Predose and 4, 12, 24, 96, 120, 144, 168, 192, 240, 336, 504, and 672 hours postdose
Reported as:
Geometric mean · h*pmol/10^6 cells
Area Under the Concentration-Time Curve From Predose to Last Measurable Concentration (AUC0-last) of MK-8527-TP in PBMCs
h*pmol/10^6 cellsPanel A: MK-8527 1.0 mgPanel B: MK-8527 0.5 mgPanel C: MK-8527 0.25 mg
Area Under the Concentration-Time Curve From Predose to Last Measurable Concentration (AUC0-last) of MK-8527-TP in PBMCs40.9 (32.5 to 51.4)17.1 (13.1 to 22.2)5.88 (4.51 to 7.66)
SecondaryMaximum Concentration (Cmax) of MK-8527-TP in PBMCs

The MK-8527-TP Cmax in PBMCs is reported.

Time frame:
Predose and 4, 12, 24, 96, 120, 144, 168, 192, 240, 336, 504, and 672 hours postdose
Reported as:
Geometric mean · pmol/10^6 cells
Maximum Concentration (Cmax) of MK-8527-TP in PBMCs
pmol/10^6 cellsPanel A: MK-8527 1.0 mgPanel B: MK-8527 0.5 mgPanel C: MK-8527 0.25 mg
Maximum Concentration (Cmax) of MK-8527-TP in PBMCs0.270 (0.232 to 0.314)0.134 (0.113 to 0.160)0.0535 (0.0449 to 0.0637)
SecondaryConcentration at 168 Hours Postdose (C168) of MK-8527-TP in PBMCs

The C168 of MK-8527-TP in PBMCs is reported.

Time frame:
168 hours postdose
Reported as:
Geometric mean · pmol/10^6 cells
Concentration at 168 Hours Postdose (C168) of MK-8527-TP in PBMCs
pmol/10^6 cellsPanel A: MK-8527 1.0 mgPanel B: MK-8527 0.5 mgPanel C: MK-8527 0.25 mg
Concentration at 168 Hours Postdose (C168) of MK-8527-TP in PBMCs0.111 (0.0808 to 0.152)0.0484 (0.0344 to 0.0681)0.0224 (0.0154 to 0.0325)
SecondaryTime to Maximum Concentration (Tmax) of MK-8527-TP in PBMCs

The MK-8527-TP Tmax in PBMCs is reported.

Time frame:
Predose and 4, 12, 24, 96, 120, 144, 168, 192, 240, 336, 504, and 672 hours postdose
Reported as:
Median · hours
Time to Maximum Concentration (Tmax) of MK-8527-TP in PBMCs
hoursPanel A: MK-8527 1.0 mgPanel B: MK-8527 0.5 mgPanel C: MK-8527 0.25 mg
Time to Maximum Concentration (Tmax) of MK-8527-TP in PBMCs24.00 (12.00 to 24.05)24.03 (12.07 to 24.68)23.91 (12.00 to 24.12)
SecondaryApparent Terminal Half-life (t½) of MK-8527-TP in PBMCs

The apparent t½ of MK-8527-TP in PBMCs is reported.

Time frame:
Predose and 4, 12, 24, 96, 120, 144, 168, 192, 240, 336, 504, and 672 hours postdose
Reported as:
Geometric mean · Hours
Apparent Terminal Half-life (t½) of MK-8527-TP in PBMCs
HoursPanel A: MK-8527 1.0 mgPanel B: MK-8527 0.5 mgPanel C: MK-8527 0.25 mg
Apparent Terminal Half-life (t½) of MK-8527-TP in PBMCs128.24 ± 49.00172.09 ± 90.2380.15 ± 52.35
SecondaryAUC0-inf of MK-8527 in Plasma

The AUC0-inf of MK-8527 in plasma is reported.

Time frame:
Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose
Reported as:
Geometric mean · h*umol/L
AUC0-inf of MK-8527 in Plasma
h*umol/LPanel A: MK-8527 1.0 mgPanel B: MK-8527 0.5 mgPanel C: MK-8527 0.25 mg
AUC0-inf of MK-8527 in Plasma0.0512 (0.0360 to 0.0728)NA (NA to NA)NA (NA to NA)
SecondaryAUC0-last of MK-8527 in Plasma

The AUC0-last of MK-8527 in plasma is reported.

Time frame:
Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose
Reported as:
Geometric mean · h*umol/L
AUC0-last of MK-8527 in Plasma
h*umol/LPanel A: MK-8527 1.0 mgPanel B: MK-8527 0.5 mgPanel C: MK-8527 0.25 mg
AUC0-last of MK-8527 in Plasma0.0304 (0.0221 to 0.0419)NA (NA to NA)NA (NA to NA)
SecondaryClast of MK-8527 in Plasma

The Clast of MK-8527 in plasma is reported.

Time frame:
Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose
Reported as:
Geometric mean · umol/L
Clast of MK-8527 in Plasma
umol/LPanel A: MK-8527 1.0 mgPanel B: MK-8527 0.5 mgPanel C: MK-8527 0.25 mg
Clast of MK-8527 in Plasma0.00388 (0.00346 to 0.00435)0.00433 (0.00380 to 0.00495)0.00417 (0.00361 to 0.00482)
SecondaryCmax of MK-8527 in Plasma

The Cmax of MK-8527 in plasma is reported.

Time frame:
Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose
Reported as:
Geometric mean · umol/L
Cmax of MK-8527 in Plasma
umol/LPanel A: MK-8527 1.0 mgPanel B: MK-8527 0.5 mgPanel C: MK-8527 0.25 mg
Cmax of MK-8527 in Plasma0.0224 (0.0172 to 0.0292)0.00935 (0.00688 to 0.0127)0.00469 (0.00335 to 0.00656)
SecondaryTmax of MK-8527 in Plasma

The Tmax of MK-8527 in plasma is reported.

Time frame:
Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose
Reported as:
Median · Hours
Tmax of MK-8527 in Plasma
HoursPanel A: MK-8527 1.0 mgPanel B: MK-8527 0.5 mgPanel C: MK-8527 0.25 mg
Tmax of MK-8527 in Plasma0.50 (0.50 to 1.00)0.50 (0.50 to 3.00)0.50 (0.23 to 1.00)
SecondaryApparent t½ of MK-8527 in Plasma

The apparent t½ of MK-8527 in plasma is reported.

Time frame:
Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose
Reported as:
Geometric mean · Hours
Apparent t½ of MK-8527 in Plasma
HoursPanel A: MK-8527 1.0 mgPanel B: MK-8527 0.5 mgPanel C: MK-8527 0.25 mg
Apparent t½ of MK-8527 in Plasma3.25 ± 54.52NA ± NANA ± NA
SecondaryCorrelation Between Intracellular C168 of MK-8527-TP in PBMCs and Change From Baseline in Plasma HIV-1 RNA

The correlation between between the C168 of MK-8527-TP in PBMCs and the change from baseline in plasma HIV-1 RNA levels 168 hours after dosing was calculated based on all pooled participants. All participants who complied with the protocol sufficiently to ensure that generated data will belikely to exhibit the effects of treatment, according to the underlying scientific model, are included. Participants with data below the LLOQ are excluded.

Time frame:
Predose and 168 hours postdose
Reported as:
Number · Pearson r coefficient
Correlation Between Intracellular C168 of MK-8527-TP in PBMCs and Change From Baseline in Plasma HIV-1 RNA
Pearson r coefficientPanel A: MK-8527 1.0 mgPanel B: MK-8527 0.5 mgPanel C: MK-8527 0.25 mgPanels A to C: MK-8527 Pooled
Correlation Between Intracellular C168 of MK-8527-TP in PBMCs and Change From Baseline in Plasma HIV-1 RNANANANA-0.342

Adverse events

Collected over Up to 28 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panel A: MK-8527 1.0 mg0/8 (0%)0/8 (0%)5/8 (62.5%)
Panel B: MK-8527 0.5 mg0/6 (0%)0/6 (0%)5/6 (83.3%)
Panel D: MK-8527 0.25 mg0/6 (0%)0/6 (0%)2/6 (33.3%)
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPanel A: MK-8527 1.0 mgPanel B: MK-8527 0.5 mgPanel D: MK-8527 0.25 mg
HeadacheNervous system disorders2/81/61/6
DiarrhoeaGastrointestinal disorders0/81/60/6
DyspepsiaGastrointestinal disorders0/80/61/6
NauseaGastrointestinal disorders0/81/60/6
Vessel puncture site bruiseGeneral disorders0/81/60/6
ImpetigoInfections and infestations1/81/60/6
Tinea facieiInfections and infestations1/81/60/6
Urinary tract infectionInfections and infestations1/81/60/6
CarbuncleInfections and infestations0/81/60/6
FuruncleInfections and infestations0/81/60/6

Baseline characteristics

There were no participants in Panel D.

Age, Continuous
Age, Continuous(years)Panel A: MK-8527 1.0 mgPanel B: MK-8527 0.5 mgPanel C: MK-8527 0.25 mgTotal
Mean30.0 ± 8.623.8 ± 3.537.8 ± 12.630.5 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)Panel A: MK-8527 1.0 mgPanel B: MK-8527 0.5 mgPanel C: MK-8527 0.25 mgTotal
Female56213
Male3047
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Panel A: MK-8527 1.0 mgPanel B: MK-8527 0.5 mgPanel C: MK-8527 0.25 mgTotal
Hispanic or Latino0000
Not Hispanic or Latino86620
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Panel A: MK-8527 1.0 mgPanel B: MK-8527 0.5 mgPanel C: MK-8527 0.25 mgTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American86216
White0044
More than one race0000
Unknown or Not Reported0000
08

Study locations

4 sites
  • ARENSIA Exploratory Medicine-Institutul National de Boli Infectioase Matei Bals ( Site 0004)
    București, Bucuresti, Romania
  • Josha Research ( Site 0003)
    Bloemfontein, Free State 9301, South Africa
  • Helen Joseph Hospital-Clinical HIV Research Unit ( Site 0002)
    Johannesburg, Gauteng 2092, South Africa
  • Desmond Tutu Health Foundation ( Site 0001)
    Cape Town, Western Cape 7925, South Africa
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Jan 2024, 14 months.

Results were first posted in Mar 2025, 1 year 1 month after primary completion.

Of 76 industry-sponsored phase 1 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 14 months is above that.

Counting every sponsor, half of 139 studies reached it within 14 months; a quarter within 4 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2022
First posted
Aug 10, 2022
StartActual
Nov 17, 2022
Primary completionActual
Jan 31, 2024
CompletionActual
Jan 31, 2024
Results first posted
Mar 26, 2025
Last update
Mar 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05494736
Responsible party
Sponsor
First posted
Aug 10, 2022
Start date
Nov 17, 2022
Primary completion
Jan 31, 2024
Completion
Jan 31, 2024
Results posted
Mar 26, 2025
Last update
Mar 26, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alimatravir

Start the discussion